EDAP Announces Positive Results from the FARP Randomized Controlled Trial Presented at the American Urological Association (AUA) Annual Meeting

"The positive results from the FARP randomized controlled trial further validate the role of robotic focal ablation with ultrasound energy in the management of prostate cancer," said Ryan Rhodes, Chief Executive Officer of EDAP TMS. "Focal One Robotic HIFU was used for the vast majority of the patients treated with focal ablation in this study. This demonstrates Focal One's leadership position in the rapidly growing treatment category of focal therapy for prostate cancer. We anticipate that the positive dat ...